


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit 1655



Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
JK	AA	Hudes, G.R., "Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer", <u>J. Clin Oncol.</u> , 15(9):3156-63 (1997).
N	AB	Matsuoka, M., "Comparison of the effects of l-carnitine, d-carnitine and acetyl-l-carnitine on the neurotoxicity of ammonia", <u>Biochemical Pharmacology</u> , (46(1):159-164 (1993).
W	AC	Mead Johnson Oncology Products, Taxol (Paclitaxel) Injection Labeling Revision (04/09/98).
W	AD	Rinehart, K., "Antitumor compounds from tunicates", <u>Medicinal Research Reviews</u> , 20(1):1-27; <u>Wiley Interactive Science Journal</u> , Pub. online 12/22/99.
V	AE	Virmani, M.A., "Protective actions of l-carnitine and acetyl-l-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors", <u>Pharmacological Research</u> , 32(6):383-389 (1995).

Examiner Signature 	Date Considered 09/18/06
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	